Financial Advantage’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $1.66M | Sell |
22,737
-14,427
| -39% | -$1.15M | 2.55% | 18 |
|
|
2023
Q2 | $3.09M | Buy |
37,164
+705
| +2% | +$59K | 2.77% | 16 |
|
|
2023
Q1 | $2.78M | Sell |
36,459
-105
| -0.3% | -$8.71K | 2.52% | 21 |
|
|
2022
Q4 | $3.03M | Buy |
36,564
+110
| +0.3% | +$8.91K | 2.82% | 17 |
|
|
2022
Q3 | $2.89M | Sell |
36,454
-19
| -0.1% | -$1.6K | 2.85% | 16 |
|
|
2022
Q2 | $2.71M | Buy |
36,473
+950
| +3% | +$71.3K | 2.49% | 20 |
|
|
2022
Q1 | $3.19M | Buy |
35,523
+22,482
| +172% | +$2.08M | 2.58% | 18 |
|
|
2021
Q4 | $1.46M | Buy |
13,041
+6
| +0% | +$724 | 1.21% | 25 |
|
|
2021
Q3 | $1.64M | Buy |
13,035
+211
| +2% | +$27.2K | 1.42% | 25 |
|
|
2021
Q2 | $1.74M | Sell |
12,824
-147
| -1% | -$19.3K | 1.48% | 25 |
|
|
2021
Q1 | $1.76M | Buy |
12,971
+793
| +7% | +$119K | 1.52% | 25 |
|
|
2020
Q4 | $1.71M | Sell |
12,178
-1,263
| -9% | -$162K | 1.59% | 22 |
|
|
2020
Q3 | $1.5M | Sell |
13,441
-8,094
| -38% | -$907K | 1.42% | 23 |
|
|
2020
Q2 | $2.41M | Sell |
21,535
-843
| -4% | -$83K | 1.82% | 22 |
|
|
2020
Q1 | $1.73M | Buy |
22,378
+6,478
| +41% | +$574K | 1.51% | 23 |
|
|
2019
Q4 | $1.51M | Sell |
15,900
-16
| -0.1% | -$1.38K | 1.04% | 23 |
|
|
2019
Q3 | $1.21M | Buy |
15,916
+567
| +4% | +$47.1K | 0.83% | 24 |
|
|
2019
Q2 | $1.35M | Buy |
15,349
+93
| +0.6% | +$7.93K | 0.92% | 24 |
|
|
2019
Q1 | $1.38M | Sell |
15,256
-19
| -0.1% | -$1.62K | 0.98% | 25 |
|
|
2018
Q4 | $1.1M | Sell |
15,275
-108
| -0.7% | -$8.7K | 0.9% | 24 |
|
|
2018
Q3 | $1.48M | Buy |
15,383
+1,340
| +10% | +$130K | 1.11% | 24 |
|
|
2018
Q2 | $1.34M | Buy |
14,043
+495
| +4% | +$45.5K | 1.01% | 24 |
|
|
2018
Q1 | $1.19M | Sell |
13,548
-406
| -3% | -$37.1K | 0.95% | 25 |
|
|
2017
Q4 | $1.18M | Buy |
13,954
+329
| +2% | +$27.6K | 0.94% | 24 |
|
|
2017
Q3 | $1.18M | Buy |
13,625
+268
| +2% | +$21.5K | 0.96% | 24 |
|
|
2017
Q2 | $1.03M | Buy |
13,357
+359
| +3% | +$25.5K | 0.87% | 25 |
|
|
2017
Q1 | $901K | Buy |
12,998
+211
| +2% | +$14.2K | 0.76% | 24 |
|
|
2016
Q4 | $757K | Buy |
12,787
+685
| +6% | +$42.3K | 0.69% | 24 |
|
|
2016
Q3 | $802K | Sell |
12,102
-267
| -2% | -$16.5K | 0.74% | 22 |
|
|
2016
Q2 | $669K | Buy |
12,369
+241
| +2% | +$13.2K | 0.6% | 24 |
|
|
2016
Q1 | $627K | Buy |
12,128
+584
| +5% | +$30.3K | 0.57% | 24 |
|
|
2015
Q4 | $810K | Sell |
11,544
-113
| -1% | -$7.71K | 0.85% | 22 |
|
|
2015
Q3 | $726K | Buy |
11,657
+1,394
| +14% | +$110K | 0.68% | 23 |
|
|
2015
Q2 | $863K | Sell |
10,263
-639
| -6% | -$49.7K | 0.83% | 21 |
|
|
2015
Q1 | $819K | Sell |
10,902
-12,921
| -54% | -$903K | 0.72% | 22 |
|
|
2014
Q4 | $1.48M | Sell |
23,823
-1,581
| -6% | -$90.1K | 1.37% | 20 |
|
|
2014
Q3 | $1.32M | Buy |
25,404
+942
| +4% | +$48K | 1.25% | 20 |
|
|
2014
Q2 | $1.26M | Buy |
24,462
+621
| +3% | +$28K | 1.23% | 19 |
|
|
2014
Q1 | $1.13M | Sell |
23,841
-1,854
| -7% | -$94.9K | 1.1% | 20 |
|
|
2013
Q4 | $1.11M | Sell |
25,695
-13,917
| -35% | -$576K | 0.94% | 20 |
|
|
2013
Q3 | $1.71M | Buy |
39,612
+195
| +0.5% | +$7.9K | 1.47% | 20 |
|
|
2013
Q2 | $1.37M | Buy |
+39,417
| New | +$1.39M | 1.19% | 21 |
|
Other funds holding XBI
PF
Financial Advantage's XBI Position: Q3 2023 in Review
Financial Advantage reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 39% in Q3 2023, selling an estimated $1.15M and leaving 22,737 shares worth $1.66M. The position accounts for 2.55% of the portfolio, ranked #18.
Financial Advantage first reported a position in XBI in Q2 2013 and has held it in 42 quarters since. The position peaked at $3.19M in Q1 2022. 679 funds tracked by Wall St. Rank hold XBI as of Q3 2023.
- Financial Advantage held 22,737 shares of State Street SPDR S&P Biotech ETF worth $1.66M as of Q3 2023.
- Financial Advantage sold 14,427 State Street SPDR S&P Biotech ETF shares in Q3 2023, an estimated $1.15M.
- State Street SPDR S&P Biotech ETF made up 2.55% of Financial Advantage's portfolio in Q3 2023, its #18 holding.
- Financial Advantage first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 42 quarters since.
- Financial Advantage's State Street SPDR S&P Biotech ETF position peaked at $3.19M in Q1 2022.
- 679 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2023.
Based on Financial Advantage's 13F filing for Q3 2023, filed 7 Nov 2023.